Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Medical technology & services

The Afterhours — Adobe reports; Etsy announces layoffs

Adobe Inc (NASDAQ:ADBE) stock fell more than 6% in extended trading Wednesday after the company’s fiscal 2024 guidance fell short of expectations.

The creative software company posted fiscal fourth-quarter adjusted earnings of $4.27, topping expectations of $4.14 per share. Revenue was $5.05 billion, up 12% year over year and above expectations of $5.03 billion.

Etsy (NASDAQ:ETSY) is slashing its headcount by 11% during the holiday shopping season, the company announced Wednesday, citing a “very challenging macro and competitive environment.”

The cuts will affect around 225 Etsy employees, bringing the DIY e-commerce site’s headcount to about 1,770. That’s roughly where things stood in early 2022, according to reports.

Meanwhile, Vertex Pharmaceuticals (NASDAQ:VRTX) shares surged more than 13% on Wednesday after the company announced an agreement to license CRISPR-Cas9 gene-editing technology from Editas Medicines.

In exchange for $100 million plus potential licensing fees, Vertex got non-exclusive licensing rights to medicines targeting the BCL11A gene in Sickle Cell Disease. That includes Casgevy, which was approved by the Food and Drug Administration (FDA) earlier this month.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK